Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?

In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and alerts, potentially leading users to act on outdated data. The recalls highlight the growing importance of Dexcom’s software quality and real-time data integrity, especially as its CGM ecosystem becomes more deeply embedded in everyday diabetes management across multiple countries and devices. We’ll...